Cue Biopharma
37 hedge funds and large institutions have $32.4M invested in Cue Biopharma in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Holders
37
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$3.89M | |
| 2 | +$466K | |
| 3 | +$453K | |
| 4 |
Morgan Stanley
New York
|
+$355K |
| 5 |
BlackRock
New York
|
+$240K |
Top Sellers
| 1 | -$2.31M | |
| 2 | -$179K | |
| 3 | -$166K | |
| 4 |
Goldman Sachs
New York
|
-$147K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$60.8K |